Published in Oncol Rev on May 09, 2017
Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 27.85
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature (2005) 6.60
Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 6.57
Integrin signalling during tumour progression. Nat Rev Mol Cell Biol (2004) 6.53
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
The clinical course of bone metastases from breast cancer. Br J Cancer (1987) 4.93
Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol (1998) 4.41
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
Denosumab and bisphosphonates: different mechanisms of action and effects. Bone (2010) 2.37
Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol (2010) 2.33
The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer (1982) 2.20
Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer (1998) 2.20
Staging non-small cell lung cancer with whole-body PET. Radiology (1999) 2.07
Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol (2011) 1.84
Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology (1996) 1.72
Bone metastases: pathophysiology and management policy. J Clin Oncol (1991) 1.70
Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res (1990) 1.54
Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med (1999) 1.53
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol (2011) 1.51
Critical steps in hematogenous metastasis: an overview. Surg Oncol Clin N Am (2001) 1.48
Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol (2014) 1.46
Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev (2001) 1.41
Overview of bisphosphonates. Cancer (1997) 1.40
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res (2013) 1.33
Radiation for bone metastases: conventional techniques and the role of systemic radiopharmaceuticals. Cancer (1997) 1.32
Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone (1994) 1.31
Transcription factors in bone: developmental and pathological aspects. Trends Mol Med (2002) 1.30
Mechanisms of cancer metastasis to bone. J Bone Joint Surg Am (1986) 1.28
Adhesion and homing of blood-borne cells in bone marrow microvessels. J Leukoc Biol (1999) 1.28
Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial. Cancer (2012) 1.25
The management of pathological fractures. J Trauma (1965) 1.19
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer (2010) 1.18
The spread of prostatic carcinoma to the bones. J Pathol Bacteriol (1953) 1.18
Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev (1996) 1.13
Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol (2002) 1.12
Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol (2010) 1.12
Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology (1996) 1.12
CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg (2004) 1.12
Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol (1997) 1.11
Radiologic diagnosis of bone metastases. Cancer (1997) 1.08
Bone cancer pain. Cancer (2003) 1.06
Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. Radiographics (1991) 1.04
Management of bone metastases in cancer: a review. Crit Rev Oncol Hematol (2005) 1.03
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging (2012) 0.98
The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin Oncol (2001) 0.98
Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res (2009) 0.97
Novel therapeutic approaches to cancer patients with bone metastasis. Crit Rev Oncol Hematol (2001) 0.97
Use of bisphosphonates in cancer patients. Cancer Treat Rev (1996) 0.96
The role of stereotactic radiosurgery in metastasis to the spine. J Korean Neurosurg Soc (2012) 0.93
Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake. Pharm Res (1997) 0.92
Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report. Cancer (1986) 0.91
Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis. PLoS One (2012) 0.91
How is androgen-dependent metastatic prostate cancer best treated? Hematol Oncol Clin North Am (1996) 0.89
Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev (2010) 0.89
CT for monitoring cryotherapy. AJR Am J Roentgenol (1996) 0.88
Stereotactic body radiotherapy in the management of painful bone metastases. Oncology (Williston Park) (2008) 0.87
Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochim Biophys Acta (2012) 0.87
Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol (2006) 0.86
The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases. Surg Today (1994) 0.86
A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases. Int J Radiat Oncol Biol Phys (1992) 0.86
Palliation of painful metastatic disease involving bone with imaging-guided treatment: comparison of patients' immediate response to radiofrequency ablation and cryoablation. AJR Am J Roentgenol (2011) 0.85
Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Ther Adv Urol (2012) 0.83
Magnetic resonance imaging versus radionuclide scintigraphy for screening in bone metastases. Clin Radiol (2000) 0.82
Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs (2003) 0.81
[Effect of bisphosphonates on anticancer activity in prostate cancer cells]. Yakugaku Zasshi (2012) 0.80
Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion. Ther Adv Med Oncol (2011) 0.79
Clinical experience with strontium-89 in prostatic and breast cancer patients. Semin Oncol (1993) 0.79